Protocol for a pilot randomised controlled trial of zoledronic acid to prevent bone loss following sleeve gastrectomy surgery

Laura E Flores, Lynn Mack, Christopher Wichman, Ashley A Weaver, Vishal Kothari, Laura D Bilek, Laura E Flores, Lynn Mack, Christopher Wichman, Ashley A Weaver, Vishal Kothari, Laura D Bilek

Abstract

Introduction: Sleeve gastrectomy (SG) is an increasingly used and effective treatment for obesity; however, the rapid weight loss associated with SG adversely affects bone metabolism predisposing patients to skeletal fragility. Bisphosphonate medications have been evaluated for safety and efficacy in combating bone loss in patients with osteoporosis, but their use in SG-induced bone loss is limited. The goal of this study is to investigate how a one-time infusion of zoledronic acid compares to placebo, in its ability to combat SG-associated bone loss.

Methods and analysis: This research protocol is a 9-month, pilot randomized controlled trial (RCT) involving 30 adult SG patients randomised to receive an infusion of either 5 mg of zoledronic acid or placebo, 6 weeks following surgery. To be included participants must be <350 lbs/158.8 kg, free of bone-impacting pathologies or medications, and must have adequate serum calcium and vitamin D levels at baseline. The primary outcome is change in areal bone mineral density (aBMD) at the total hip. Secondary outcomes include change in aBMD of the femoral neck, and lumbar spine, and change in volumetric BMD at the lumbar spine. The primary aim will be tested using a linear mixed model fit with total hip aBMD at 9 months as the outcome. Treatment, participant sex and menopausal status will be considered in analysis. Groups will be compared using contrast statements at 9 months, with change over 9 months being the primary comparison.

Ethics and dissemination: This study was approved by the Institutional Review Board of the University of Nebraska Medical Center (IRB820-19). Written consent will be obtained from participants at enrolment by trained staff. Careful and thorough explanation are used in obtainment of consent and voluntariness is emphasised throughout the trial. The findings of this study will be presented locally, nationally, and published in peer-reviewed journals. Additional details will be reported on ClinicalTrials.gov.

Trial registration number: NCT04279392.

Keywords: adult gastroenterology; calcium & bone; general endocrinology; malabsorption.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Healthy body, healthy bones study design. AE, Adverse event.

References

    1. Chang S-H, Stoll CRT, Song J, et al. . The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275–87. 10.1001/jamasurg.2013.3654
    1. Schauer PR, Kashyap SR, Wolski K, et al. . Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–76. 10.1056/NEJMoa1200225
    1. American Society for Metabolic and Bariatric Surgery . Estimate of bariatric surgery numbers, 2011-2018. ASMBS, 2020. Available: [Accessed 20 Feb 2020].
    1. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and management. Lancet Diabetes Endocrinol 2014;2:165–74. 10.1016/S2213-8587(13)70183-9
    1. Beavers KM, Greene KA, Yu EW. Management of endocrine disease: bone complications of bariatric surgery: updates on sleeve gastrectomy, fractures, and interventions. Eur J Endocrinol 2020;183:R119–32. 10.1530/EJE-20-0548
    1. Coates PS, Fernstrom JD, Fernstrom MH, et al. . Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004;89:1061–5. 10.1210/jc.2003-031756
    1. Gagnon C, Schafer AL. Bone health after bariatric surgery. JBMR Plus 2018;2:121–33. 10.1002/jbm4.10048
    1. Finkelstein JS, Brockwell SE, Mehta V, et al. . Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861–8. 10.1210/jc.2007-1876
    1. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032–45. 10.4065/83.9.1032
    1. Davis S, Martyn-St James M, Sanderson J, et al. . A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1–406. 10.3310/hta20780
    1. Liu Y, Côté MM, Cheney MC, et al. . Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery. Bone Rep 2021;14:100760. 10.1016/j.bonr.2021.100760
    1. Beavers KM, Beavers DP, Fernandez AZ, et al. . Risedronate use to attenuate bone loss following sleeve gastrectomy: results from a pilot randomized controlled trial. Clin Obes 2021;11:e12487. 10.1111/cob.12487
    1. Vieira HP, Leite IA, Araújo Sampaio TM, et al. . Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med 2013;6:24. 10.1186/1755-7682-6-24
    1. Yamamoto K, Kishino M, Nakamura S, et al. . Symptoms and upper gastrointestinal mucosal injury associated with bisphosphonate therapy. Intern Med 2019;58:1049–56. 10.2169/internalmedicine.1271-18
    1. Black DM, Delmas PD, Eastell R, et al. . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22. 10.1056/NEJMoa067312
    1. Fobelo Lozano MJ, Sánchez-Fidalgo S. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. Eur J Hosp Pharm 2019;26:4–9. 10.1136/ejhpharm-2017-001258
    1. Mechanick JI, Apovian C, Brethauer S, et al. . Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Endocrine Practice 2019;25:1–75. 10.4158/GL-2019-0406
    1. Davidson M, de Morton N. A systematic review of the human activity profile. vol 21, 2007: 151–62.
    1. Tamura LS, Cazzo E, Chaim EA, et al. . Influence of morbid obesity on physical capacity, knee-related symptoms and overall quality of life: a cross-sectional study. Rev Assoc Med Bras 2017;63:142–7. 10.1590/1806-9282.63.02.142
    1. National Osteoporosis Foundation . Steps to estimate your calcium intake. National osteoporosis Foundation, 2021. Available: [Accessed 20 Aug 2021].
    1. Reinmann A, Gafner SC, Hilfiker R, et al. . Bariatric surgery: consequences on functional capacities in patients with obesity. Front Endocrinol 2021;12:646283. 10.3389/fendo.2021.646283
    1. Otto M, Kautt S, Kremer M, et al. . Handgrip strength as a predictor for post bariatric body composition. Obes Surg 2014;24:2082–8. 10.1007/s11695-014-1299-6
    1. Peters DM, Fritz SL, Krotish DE. Assessing the reliability and validity of a shorter walk test compared with the 10-Meter walk test for measurements of gait speed in healthy, older adults. J Geriatr Phys Ther 2013;36:24–30. 10.1519/JPT.0b013e318248e20d
    1. Shepherd JA, Ng BK, Sommer MJ, et al. . Body composition by DXA. Bone 2017;104:101–5. 10.1016/j.bone.2017.06.010
    1. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a who report. who Study Group. Osteoporos Int 1994;4:368–81. 10.1007/BF01622200
    1. Schoell SL, Beavers KM, Beavers DP, et al. . Prediction of lumbar vertebral body compressive strength of overweight and obese older adults using morphed subject-specific finite-element models to evaluate the effects of weight loss. Aging Clin Exp Res 2019;31:491–501. 10.1007/s40520-018-1010-1
    1. Beavers KM, Walkup MP, Weaver AA, et al. . Effect of exercise modality during weight loss on bone health in older adults with obesity and cardiovascular disease or metabolic syndrome: a randomized controlled trial. J Bone Miner Res 2018;33:2140–9. 10.1002/jbmr.3555
    1. Whitney SL, Wrisley DM, Marchetti GF, et al. . Clinical measurement of sit-to-stand performance in people with balance disorders: validity of data for the Five-Times-Sit-to-Stand test. Phys Ther 2005;85:1034–45. 10.1093/ptj/85.10.1034
    1. Vasikaran S, Eastell R, Bruyère O, et al. . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391–420. 10.1007/s00198-010-1501-1
    1. Borba VZC, Paz-Filho G, Kulak CAM, et al. . Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract 2007;61:1058–62. 10.1111/j.1742-1241.2007.01392.x
    1. Hosking D, Lyles K, Brown JP, et al. . Long-Term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142–8. 10.1359/jbmr.061001
    1. Ofotokun I, Collins LF, Titanji K, et al. . Antiretroviral therapy-induced bone loss is durably suppressed by a single dose of zoledronic acid in treatment-naive persons with human immunodeficiency virus infection: a phase IIb trial. Clin Infect Dis 2020;71:1655–63. 10.1093/cid/ciz1027
    1. Brown JE, Ellis SP, Lester JE, et al. . Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007;13:5406–10. 10.1158/1078-0432.CCR-07-0247
    1. Hofsø D, Hillestad TOW, Halvorsen E, et al. . Bone mineral density and turnover after sleeve gastrectomy and gastric bypass: a randomized controlled trial (Oseberg). J Clin Endocrinol Metab 2021;106:501–11. 10.1210/clinem/dgaa808
    1. Crawford MR, Pham N, Khan L, et al. . Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery versus medical therapy at 5 years. Endocr Pract 2018;24:256–64. 10.4158/EP-2017-0072
    1. Chakhtoura M, Rahme M, El-Hajj Fuleihan G. Vitamin D metabolism in bariatric surgery. Endocrinol Metab Clin North Am 2017;46:947–82. 10.1016/j.ecl.2017.07.006
    1. Carrasco F, Basfi-Fer K, Rojas P, et al. . Calcium absorption may be affected after either sleeve gastrectomy or Roux-en-Y gastric bypass in premenopausal women: a 2-y prospective study. Am J Clin Nutr 2018;108:24–32. 10.1093/ajcn/nqy071
    1. Altieri MS, Yang J, Groves D, et al. . Sleeve Gastrectomy: the first 3 Years: evaluation of emergency department visits, readmissions, and reoperations for 14,080 patients in New York State. Surg Endosc 2018;32:1209–14. 10.1007/s00464-017-5793-5

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する